On Jan 12, the company provided a report on study of patients with Duchenne muscular dystrophy (“DMD”) treatment known as eteplirsen. The report confirmed that patients undergoing the treatment showed decline in distance walked in the 168th week compared to the previous update after week 144.
The biomedicine company has seen a flat track record when it comes to current year estimate revisions over the past few weeks and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
SRPT currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Another better-ranked stock in the same sector is Affymetrix Inc. (AFFX).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment